These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 1356011)
21. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. Günthert AR; Gründker C; Olota A; Läsche J; Eicke N; Emons G Eur J Endocrinol; 2005 Oct; 153(4):613-25. PubMed ID: 16189183 [TBL] [Abstract][Full Text] [Related]
22. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142 [TBL] [Abstract][Full Text] [Related]
23. Regulation of the pituitary 5 alpha-reductase activity by gonadotropin releasing hormone and testosterone in the adult male rat. Vanderstichele H; Eechaute W; Lacroix E J Steroid Biochem; 1990 Apr; 35(5):575-81. PubMed ID: 2141376 [TBL] [Abstract][Full Text] [Related]
24. Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin. de Quijada MG; Redding TW; Coy DH; Torres-Aleman I; Schally AV Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3485-8. PubMed ID: 6134284 [TBL] [Abstract][Full Text] [Related]
25. Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate. Qin Y; Ertl T; Groot K; Horvath J; Cai RZ; Schally AV Int J Cancer; 1995 Mar; 60(5):694-700. PubMed ID: 7860145 [TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Pinski J; Reile H; Halmos G; Groot K; Schally AV Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203 [TBL] [Abstract][Full Text] [Related]
27. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. Limonta P; Dondi D; Moretti RM; Maggi R; Motta M J Clin Endocrinol Metab; 1992 Jul; 75(1):207-12. PubMed ID: 1320049 [TBL] [Abstract][Full Text] [Related]
28. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931 [TBL] [Abstract][Full Text] [Related]
29. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Sharoni Y; Bosin E; Miinster A; Levy J; Schally AV Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1648-51. PubMed ID: 2646641 [TBL] [Abstract][Full Text] [Related]
34. Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development. Yano T; Yano N; Matsumi H; Morita Y; Tsutsumi O; Schally AV; Taketani Y Horm Res; 1997; 48 Suppl 3():35-41. PubMed ID: 9267814 [TBL] [Abstract][Full Text] [Related]
35. Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships. Mezö I; Lovas S; Pályi I; Vincze B; Kálnay A; Turi G; Vadász Z; Seprödi J; Idei M; Tóth G; Gulyás E; Otvös F; Mák M; Horváth JE; Teplán I; Murphy RF J Med Chem; 1997 Oct; 40(21):3353-8. PubMed ID: 9341910 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Redding TW; Schally AV Proc Natl Acad Sci U S A; 1984 Jan; 81(1):248-52. PubMed ID: 6141560 [TBL] [Abstract][Full Text] [Related]
37. Effects of a gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo. Maruuchi T; Sugiyama T; Kataoka A; Nishida T; Yakushiji M Jpn J Cancer Res; 1998 Sep; 89(9):977-83. PubMed ID: 9818035 [TBL] [Abstract][Full Text] [Related]
38. Evidence that signalling pathways by which thyrotropin-releasing hormone and gonadotropin-releasing hormone act are both common and distinct. Kaiser UB; Katzenellenbogen RA; Conn PM; Chin WW Mol Endocrinol; 1994 Aug; 8(8):1038-48. PubMed ID: 7527898 [TBL] [Abstract][Full Text] [Related]
39. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Gründker C; Emons G Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454 [TBL] [Abstract][Full Text] [Related]
40. Decrease in prolactin receptor affinity in the rat mammary tumor model after treatment with analogs of somatostatin and LH-RH. Kadar T; Redding TW; Ben-David M; Schally AV Mater Med Pol; 1988; 20(4):219-23. PubMed ID: 2907923 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]